AI Analysis
Summary
City, a next-generation RNAi drugmaker, priced a $200M IPO. Proceeds will support three medicines in or nearing clinical testing and earlier research into RNAi treatments that reach tissues outside the liver.
Outcome Details
Priced $200M IPO to fund three RNAi medicines in or nearing clinical testing and earlier research into extrahepatic RNAi treatments.
Importance:7/10
Sentiment:
0.40
IPORNAiofferingextrahepatic deliverypreclinicalclinical-stage
Related Companies
Read the original article
Published by BioPharma Dive on October 16, 2026 10:33 AM